button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone vs. ipilimumab alone 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		-1123 [-1891; -355] /10000
119/316 vs. 154/315		-
nivolumab plus ipilimumab vs. ipilimumab alone 2 NaN [NaN; NaN] /10000
0/0 vs. 0/0		-2409 [-3048; -1769] /10000
80/409 vs. 158/362		-
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab 1 -2185 [-3808; -562] /10000
24/68 vs. 40/70		--
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 NaN [NaN; NaN] /10000
0/0 vs. 0/0		167 [-366; 701] /10000
45/314 vs. 40/316		-
relatlimab plus nivolumab vs. nivolumab alone 1 -NaN [NaN; NaN] /10000
0/0 vs. 0/0		-
versus Standard of Care (SoC)
tremelimumab vs. Standard of Care (SoC) 1 -361 [-960; 239] /10000
260/328 vs. 271/327		--

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 1217 [-2442; 4876] /10000
12/23 vs. 4/10		-1783 [-5280; 1715] /10000
12/23 vs. 7/10		-
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 -708 [-1553; 136] /10000
93/256 vs. 112/258		-1157 [-1983; -331] /10000
148/256 vs. 179/258		-

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1 -2234 [-3124; -1345] /10000
50/210 vs. 96/208		-2694 [-3571; -1816] /10000
108/210 vs. 163/208		-
versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 --2590 [-4480; -700] /10000
30/72 vs. 25/37		-
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 152 [-583; 888] /10000
45/222 vs. 42/224		450 [-476; 1377] /10000
121/222 vs. 112/224		-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons